NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ:OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Anti-Adhesion product candidate and achieved several milestones in the fourth quarter of 2006.
